Institute of Cancer Policy, Cancer Epidemiology, Population & Global Health, School of Cancer Sciences, King's College London, UK.
Medical University of Gdansk, Dept. of Oncology and Radiotherapy, Gdansk, Poland.
Eur J Cancer. 2018 Nov;104:127-136. doi: 10.1016/j.ejca.2018.08.024. Epub 2018 Oct 20.
Cancer research is an essential part of national cancer control programmes, and the emerging economies of Central and Eastern Europe (CEE) and the Russian Federation and Central Asia (R-CA) (Commonwealth of Independent States) remain relatively understudied. Here, we map the cancer research activity from the 29 countries across these regions over a 10-year period (2007-2016), using a standard scientometric approach. Research activity was compared with the countries' wealth and with the disease burden from different cancers, and analyses were also performed by the research domain (e.g. fundamental cancer biology, surgery). We found that although there was a correlation between outputs and national wealth, there were many outliers; the CEE countries publishing relatively more, and the R-CA, less. Outputs reflected cancer burdens, but there was a relative paucity of research on lung, colorectal, gastric and pancreatic cancer, as well as research domains such as screening and palliative care. Clinical trials accounted for only 3% of all research outputs from all countries, and were very international, with on average 1.5 CEE countries and 8.0 others involved in each article, and they were heavily cited (on average, 84 times in 5 years). Poland was by far the most research-active country, but significant needs and opportunities have been identified to expand the cancer research activity in all CEE and R-CA countries to enhance national cancer control planning.
癌症研究是国家癌症控制计划的重要组成部分,而中东欧和独联体(中亚)(独立国家联合体)的新兴经济体相对研究较少。在这里,我们使用标准的科学计量学方法,绘制了这些地区 29 个国家在 10 年期间(2007-2016 年)的癌症研究活动图。将研究活动与国家财富以及不同癌症的疾病负担进行了比较,还按研究领域(例如,癌症基础生物学、外科)进行了分析。我们发现,尽管产出与国家财富之间存在相关性,但也有许多异常值;中东欧国家的出版物相对较多,而中亚国家则较少。产出反映了癌症负担,但对肺癌、结直肠癌、胃癌和胰腺癌以及筛查和姑息治疗等领域的研究相对较少。临床试验仅占所有国家研究产出的 3%,而且非常国际化,平均每篇文章有 1.5 个中东欧国家和 8.0 个其他国家参与,并且引用率很高(平均每篇文章在 5 年内被引用 84 次)。波兰是迄今为止最具研究活力的国家,但已确定在所有中东欧和中亚国家扩大癌症研究活动以加强国家癌症控制规划的必要性和机会。